Get started
ABBVIE INCABBVIE INCABBVIE INC

ABBVIE INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

4AB trade ideas

AbbVie Inc, ABBV NYSE 4HNYSE:ABBV rsi in the oversold territory, which is starting to reverse to the bull side, flipped bullish on a micro timescale, falling wedge, breaking out to the upside, first target 140.75, then possible retest before 146.26. we've been in this long term downtrend channel since April 2022, I expect to break out of it, once we test 150.36 flip it as support then go for for 175.89 previous April top. fundamentals and news tend to effect this stock a lot, so with positive momentum and good news. bullish times could be ahead. Bear scenario is we test 125 before a full reset. For the current quarter, AbbVie is expected to post earnings of $3.59 per share, indicating a change of +7.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.2% over the last 30 days. The consensus earnings estimate of $13.90 for the current fiscal year indicates a year-over-year change of +9.5%. This estimate has changed +0.2% over the last 30 days. all this is just my opinion , none of what I say should be taken as financial advice. DYOR Regards Percy
NYSE:ABBVLong
by TechnicallyBullish
ABBV ready to bounce? AbbVie Short Term We look to Buy at 138.60 (stop at 133.69) Preferred trade is to buy on dips. There is scope for mild selling at the open but losses should be limited. We therefore, prefer to fade into the dip with a tight stop in anticipation of a move back higher. Further upside is expected although we prefer to set longs at our bespoke support levels at 139.00, resulting in improved risk/reward. Our profit targets will be 152.11 and 171.00 Resistance: 146.00 / 155.00 / 172.00 Support: 139.00 / 135.00 / 126.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:ABBVLong
by Saxo
ABBV - UPDATE!I was away from TradingView for a few days, but I'm back now and continue to look at the market and look for ideas! Updating ABBV idea: Well, after the report, we teleported to shoulder level. And now several scenarios are possible: 1) Shoulder bounce 2) Shoulder breakout Which one am I more likely to go with? A shoulder breakout. But is it worth taking a position right now? I don't think it's best to be in it from the day of the report. I'm not in a position, just watching.
NYSE:ABBVShort
by Myst_Trader
2
$ABBV looking to come up on the right side of its base!Notes: * Great earnings track record * Very strong up trend on all time frames * Pays out dividends * Coming up on the right side of its base after ~4 months * Has been in a tight range of ~3.8% for the past 3 weeks Technicals: Sector: Healthcare - Drug Manufacturers - General Relative Strength vs. Sector: 1.91 Relative Strength vs. SP500: 1.54 U/D Ratio: 1.76 Base Depth: 26.75% Distance from breakout buy point: -13.75% Volume 8.02% above its 15 day avg. Trade Idea: * You can get in now as the price is very close to its 50 day line and has been using it as support for the past 3 weeks * If you want to be safe you can wait for the breakout from this tight range with a break above 154.07 * This stock usually has local tops when the price closes around 10.96% above its 50 EMA * Consider selling into strength if the price closes 10.76% to 11.16% (or higher) above its 50 EMA * The last closing price is 0.11% away from its 50 EMA
NYSE:ABBVLong
by HaseebKhan_90
Two strategy approach to ABBV, buy on throwback or a break outABBV has broken out of the falling wedge and with that, it confirmed the terminal end of the correction. With the recent cup and handle formation, we think that a bullish upside may come however, Friday's shooting star is a concern and as such, we will place the buy order at US$156.90 to confirm the breakout trade. Another strategy we have in mind is to wait until prices retrace to their nearest support at US$143.74 to anticipate a rebound.
NYSE:ABBVLong
by William-trading
ABBV - FUNCHARTS - Follow the TrendNote: Funcharts are interesting charts I have found that offer a potentially unique perspective on a stock. Sometimes I’ll throw something out there that you might find controversial or wrong headed. If that’s the case your 2 cents worth is most welcome. Abbvie (ABBV) listed on the US market sets up nicely as a Trend Following stock. If you are in Tradingview insert the Supertrend Strategy and change the inputs to a 50 period ATR length with a factor of 2 times ATR trailing stop. The strategy will buy when the daily closing price closes above the ATR trailing stop and go short when the price closes below the ATR trailing stop (shown in blue and red on the chart). A look at the performance summary for long trades shows 44% winning trend with a win:loss ratio of 2.22 with a profit of over 109% through the period. Whilst buy and hold was the best strategy overall the drawdown was much lower for the trend following strategy and almost as much money was made. Stock like this that trend nicely, whilst allowing you to manage downside risk can be used with a certain amount of leverage as it follows the age old mantra of letting profits run and cutting losses early. As with all trend following strategies, a low win rate but high win:loss ratio is to be expected.
NYSE:ABBVLong
by andrew.gibbs777